Heavy metal legends Iron Maiden brought their “The Future Past” world tour to Brooklyn on Saturday at Barclays Center. The name of their tour is literal, as it has them focusing on both 2021’s ...

In addition to releasing some of heavy metal’s greatest albums, from “The Number of the Beast” to “Powerslave” and “Seventh Son of a Seventh Son,” Iron Maiden have the rare ...

As a tribute to beloved early-days Iron Maiden singer Paul Di’Anno, who passed away on October 21, 2024, we look at the songs ...

To keep up to date with the latest Number 1s each week, sign up to our newsletter. Unsubscribe at any time.

At a recent show in Minnesota, Iron Maiden’s current frontman ... Anno said while promoting his candid 2010 autobiography, The Beast. After a short but raucous career fronting one of the ...

In September, Di'Anno released "The Book of the Beast," his first career retrospective album that featured highlights of his work since leaving Iron Maiden.Iron Maiden shared a tribute on social ...

Featured pricing is subject to change. Prepare to headbang, metalheads. On Saturday, Nov. 2, Iron Maiden drop into Brooklyn’s Barclays Center as part of their ongoing ‘Future Past Tour’ with ...

The band's debut album shot up to number four ... "The Book of the Beast" was released, featuring highlights from his solo work, along with two reimagined versions of Iron Maiden tracks, "Tomorrow ...

Here’s a look at some of the top shows coming to the region in November: Iconic metal band Iron Maiden will return to Pittsburgh for their first show here in five years on their Future Past tour.

As of October 22, 2024, the average one-year price target for Disc Medicine is $67.04/share ... The firm decreased its portfolio allocation in IRON by 10.93% over the last quarter.

But it also gives us a glimpse into the aftereffects of how artificial intelligence (AI) systems handles our data if women do decide to give up their maiden names. In the digital age, a name is ...

Wells Fargo analyst Tiago Fauth maintained a Buy rating on Disc Medicine (IRON – Research Report) yesterday and set a price target of $91.00. The company’s shares closed yesterday at $58.25.